MeiraGTx Holdings plc

MeiraGTx Holdings plc is a clinical-stage genetic medicines company focused on developing treatments for serious diseases. Its pipeline includes therapies for ocular diseases such as inherited retinal diseases and large degenerative ocular conditions. Key programs include AAV-RPE65 for RPE65-associated retinal dystrophy, AAV-CNGB3 and AAV-CNGA3 for achromatopsia, and AAV-AIPL1 for Leber congenital amaurosis 4. The company also targets neurodegenerative diseases with AAV-GAD in Phase 2 for Parkinson's disease and AAV-UPF1 for amyotrophic lateral sclerosis. Additionally, it develops AAV-AQP1 for radiation-induced xerostomia and Sjogren's syndrome. Preclinical programs address Bardet-Biedl syndrome, Alzheimer's disease, and age-related macular degeneration. MeiraGTx also has a riboswitch platform for metabolic peptide delivery and cell therapies for oncology, autoimmune disease, and pain.

MeiraGTx Holdings plc is listed on the Nasdaq Global Select Market under the ticker symbol MGTX. The company trades in US dollars (USD). Its stock is accessible to investors through US-based brokerages and is part of the Nasdaq exchange, which is one of the major stock exchanges in the United States. The listing on Nasdaq provides liquidity and visibility for the company's shares among global investors.

MeiraGTx operates in the Healthcare sector, specifically within the Biotechnology industry. As a biotechnology company, it focuses on genetic medicines, which involve using genetic material to treat or prevent diseases. The company is clinical-stage, meaning its therapies are still undergoing clinical trials and have not yet received regulatory approval for commercial sale. Its work in biotechnology involves advanced techniques like adeno-associated virus (AAV) vectors and riboswitch platforms to deliver treatments for a range of serious conditions, from inherited retinal diseases to neurodegenerative disorders.

MeiraGTx Holdings plc is headquartered in the United States. While the company is incorporated in the UK (as indicated by 'plc'), its primary operations and listing are in the US. It serves global markets, particularly focusing on patients with serious diseases in areas such as ophthalmology, neurology, and oncology. The company has collaborations with Johnson & Johnson Innovative Medicine for inherited retinal disease gene therapies and with Hologen Limited for research and development. Its therapies target conditions that affect patients worldwide, including inherited retinal dystrophies, Parkinson's disease, and xerostomia.

MeiraGTx has established key collaborations to advance its gene therapy pipeline. Notably, it has a partnership with Johnson & Johnson Innovative Medicine for the research, development, and commercialization of gene therapies targeting inherited retinal diseases. This collaboration leverages MeiraGTx's expertise in AAV-based gene therapies and Johnson & Johnson's resources in drug development and commercialization. Additionally, MeiraGTx collaborates with Hologen Limited for research, development, and manufacturing. These partnerships help accelerate the development of treatments for conditions like RPE65-associated retinal dystrophy and achromatopsia, and provide access to broader expertise and funding.